Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $11.2 Million - $18.7 Million
844,235 New
844,235 $15.3 Billion
Q4 2022

Feb 14, 2023

BUY
$20.37 - $32.9 $46.1 Million - $74.5 Million
2,264,801 New
2,264,801 $67 Billion

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $436M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Ridgeback Capital Investments L.P. Portfolio

Follow Ridgeback Capital Investments L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ridgeback Capital Investments L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ridgeback Capital Investments L.P. with notifications on news.